1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,212 | 0,250 | 19:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | JW THERAP-B (02126): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.01. | JW THERAP-B (02126): GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 29.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 22.12.25 | JW THERAP-B (02126): CONTINUING CONNECTED TRANSACTION IN RELATION TO EXTENSION OF TERM OF VECTOR SUPPLY AGREEMENT | - | HKEx | ||
| 12.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 12.12.25 | JW THERAP-B (02126): (1) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR; (2) APPOINTMENT OF CHAIRMAN OF THE BOARD; (3) RESIGNATION OF CHIEF ... | 1 | HKEx | ||
| 08.12.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - PRESENTATION OF JWCAR201 IIT STUDY DATA AT THE 67TH AMERICAN SOCIETY OF ... | - | HKEx | ||
| 28.11.25 | Imugene And JW Therapeutics Collaborate On Solid Tumor Therapy | - | RTTNews | ||
| 30.10.25 | JW THERAP-B (02126): MAJOR TRANSACTION IN RELATION TO AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT | - | HKEx | ||
| 21.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - DATA SUBMITTED FROM PHASE I STUDY OF RELMA-CEL IN CHINESE ADULT PATIENTS ... | 1 | HKEx | ||
| 10.10.25 | China Reviews JW Therapeutics' Plan to Use Own Lentiviral Vector to Cut Cost of CAR-T Cancer Drug | 1 | Yicai Global | ||
| 09.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - NATIONAL MEDICAL PRODUCTS ADMINISTRATION OFFICIALLY ACCEPTED THE POST-MARKETING ... | - | HKEx | ||
| 30.09.25 | JW THERAP-B (02126): DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 25.09.25 | JW THERAP-B (02126): 2025 INTERIM REPORT | - | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | -7,08 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| SEPTERNA | 24,180 | -0,29 % | Septerna, Inc.: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results | Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R... ► Artikel lesen |
Das Unternehmen JW CAYMAN THERAPEUTICS CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,212 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JW CAYMAN THERAPEUTICS CO LTD finden Sie auf Wallstreet Online.